TABLE 5.
Antimicrobial activities of 3,5-dioxopyrazolidines
| Compound | MIC (μg/ml) for:
|
||||||
|---|---|---|---|---|---|---|---|
| S. aureusa | E. faecalisb | MSCNSc GC6464 | S. pneumoniae GC1894d | S. pneumoniae GC1894 + BSAf | E. coli GC4559 | E. coli (imp)e BAS849 | |
| 1 | 1-2 | 0.25 | 0.5 | 0.50 | >128 | >128 | 16 |
| 2 | 2-16 | 0.25 | 16 | 0.25 | >128 | >128 | >128 |
| 3 | 1-2 | 0.25/0.5 | 2 | 0.25 | >128 | >128 | >128 |
| 4 | 8 | 4/8 | 4 | 4 | >128 | >128 | >128 |
| Fosfomycin | 4-8 | 64 | ND | 32 | 32 | 32 | 16 |
| Vancomycin | 0.5-2 | <0.12/>128 | 1 | <0.12 | <0.12 | >128 | 0.25 |
a
Values are ranges for three S. aureus strains including MRSA.
b
Values are ranges for two E. faecalis strains including VRE.
c
MSCNS, methicillin-susceptible coagulase-negative staphylococcus. ND, not determined.
d
Penicillin-resistant S. pneumoniae.
e
Strain with improved outer membrane permeability.
f
In the presence of 4% BSA.